Evaluation of direct oral anticoagulants in superficial-vein thrombosis
- PMID: 28583285
- DOI: 10.1016/S2352-3026(17)30062-5
Evaluation of direct oral anticoagulants in superficial-vein thrombosis
Comment in
-
Evaluation of direct oral anticoagulants in superficial-vein thrombosis - Authors' reply.Lancet Haematol. 2017 Jun;4(6):e254-e255. doi: 10.1016/S2352-3026(17)30086-8. Lancet Haematol. 2017. PMID: 28583286 No abstract available.
Comment on
-
Direct oral anticoagulants for superficial-vein thrombosis.Lancet Haematol. 2017 Mar;4(3):e95-e96. doi: 10.1016/S2352-3026(17)30013-3. Epub 2017 Feb 16. Lancet Haematol. 2017. PMID: 28215406 No abstract available.
-
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.Lancet Haematol. 2017 Mar;4(3):e105-e113. doi: 10.1016/S2352-3026(17)30014-5. Epub 2017 Feb 16. Lancet Haematol. 2017. PMID: 28219692 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
